• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

瑞典帕金森病的资源利用和严重程度相关成本。

Parkinson's disease in Sweden-resource use and costs by severity.

机构信息

The Swedish Institute for Health Economics, Lund, Sweden.

Department of Neurology, Rehabilitation Medicine, Memory Disorders, and Geriatrics, Skåne University Hospital, Malmö, Sweden.

出版信息

Acta Neurol Scand. 2021 Nov;144(5):592-599. doi: 10.1111/ane.13502. Epub 2021 Jul 12.

DOI:10.1111/ane.13502
PMID:34254292
Abstract

OBJECTIVES

To estimate resource use and costs, including direct and indirect costs, in relation to levels of severity in individuals with Parkinson's disease (PD) in a Swedish setting.

MATERIALS AND METHODS

Patients with idiopathic PD registered in the National Parkinson's Disease Patient Registry (PARKreg), with registrations of Hoehn and Yahr (H&Y) and "off time" in the Skåne Region, were included. Annual costs of healthcare contacts, drugs, formal and informal care, and productivity loss associated with PD were estimated using data from PARKreg linked with regional and national healthcare registers between 2013 and 2019.

RESULTS

In total, 960 patients and 1324 observations (patient-years) were included. Total average cost per patient-year was SEK 168,982 (EUR 15,958) and ranged from SEK 62,404 (EUR 5893) for H&Y stage I to SEK 1,056,324 (EUR 99,755) in H&Y stage V. The dominating part of total costs for early stages were indirect costs accounting for 50-60% while formal care made up for 55% and 81% of total costs in H&Y IV and V, respectively. Total mean costs for formal care, informal care, and productivity loss also increased with increasing off-time.

CONCLUSION

Advanced and late stages of PD are associated with significant societal costs as patients in those stages often require resource-intensive and costly formal care. Thus, there are potential savings to be made, by optimizing the pharmacological and surgical symptomatic treatment of patients with advanced disease.

摘要

目的

在瑞典环境中,估计与帕金森病(PD)个体严重程度相关的资源利用和成本,包括直接和间接成本。

材料和方法

纳入了在国家帕金森病患者登记处(PARKreg)登记的特发性 PD 患者,这些患者在斯科讷地区有 Hoehn 和 Yahr(H&Y)登记和“关闭时间”。使用 PARKreg 中的数据,结合 2013 年至 2019 年期间的区域和国家医疗保健登记处的数据,估计了与 PD 相关的医疗保健接触、药物、正式和非正式护理以及生产力损失的年度成本。

结果

总共纳入了 960 名患者和 1324 次观察(患者年)。每位患者每年的平均总成本为 168982 瑞典克朗(15958 欧元),从 H&Y 1 期的 62404 瑞典克朗(5893 欧元)到 H&Y 5 期的 1056324 瑞典克朗(99755 欧元)不等。早期阶段总成本的主要部分是间接成本,占 50-60%,而在 H&Y 4 期和 5 期,正式护理分别占总成本的 55%和 81%。随着关闭时间的增加,正式护理、非正式护理和生产力损失的总成本也呈上升趋势。

结论

PD 的晚期和晚期阶段与重大的社会成本相关,因为这些阶段的患者通常需要资源密集型和昂贵的正式护理。因此,通过优化晚期疾病患者的药物和手术症状治疗,可以节省潜在的费用。

相似文献

1
Parkinson's disease in Sweden-resource use and costs by severity.瑞典帕金森病的资源利用和严重程度相关成本。
Acta Neurol Scand. 2021 Nov;144(5):592-599. doi: 10.1111/ane.13502. Epub 2021 Jul 12.
2
Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study.生活质量和资源利用-来自晚期帕金森病护理(CLaSP)研究的瑞典数据。
Acta Neurol Scand. 2022 Jun;145(6):743-752. doi: 10.1111/ane.13611. Epub 2022 Mar 21.
3
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.瑞典帕金森病患者队列中的资源使用与成本
Mov Disord. 2002 Nov;17(6):1213-20. doi: 10.1002/mds.10262.
4
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.基于 Hoehn 和 Yahr 量表和帕金森病停用时程的患者健康状态效用:一项瑞典基于登记的 1823 例观察研究。
Pharmacoeconomics. 2021 Oct;39(10):1141-1149. doi: 10.1007/s40273-021-01056-z. Epub 2021 Jul 7.
5
Drug and treatment costs in Parkinson's disease patients in Sweden.瑞典帕金森病患者的药物和治疗费用。
Acta Neurol Scand. 2012 Feb;125(2):142-7. doi: 10.1111/j.1600-0404.2011.01517.x. Epub 2011 Apr 6.
6
Trends in resource utilization for Parkinson's disease in Germany.德国帕金森病资源利用趋势。
J Neurol Sci. 2010 Jul 15;294(1-2):18-22. doi: 10.1016/j.jns.2010.04.011. Epub 2010 May 24.
7
Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.晚期帕金森病的护理:五个欧洲国家的疾病资源利用情况。
Mov Disord. 2024 Mar;39(3):571-584. doi: 10.1002/mds.29718. Epub 2024 Feb 29.
8
The societal cost of schizophrenia in Sweden.瑞典精神分裂症的社会成本。
J Ment Health Policy Econ. 2013 Mar;16(1):13-25.
9
Health economic costs of COPD in Sweden by disease severity--has it changed during a ten years period?瑞典按疾病严重程度划分的 COPD 健康经济成本——这在十年期间发生了变化吗?
Respir Med. 2013 Dec;107(12):1931-8. doi: 10.1016/j.rmed.2013.07.012. Epub 2013 Aug 1.
10
Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study.德国晚期帕金森病患者的资源利用情况:来自 CLaSP 研究的数据。
Pharmacoeconomics. 2021 May;39(5):601-615. doi: 10.1007/s40273-021-01011-y. Epub 2021 Mar 19.

引用本文的文献

1
Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs.左旋多巴肠凝胶输注疗法治疗晚期帕金森病:一项关于瑞典实际应用和成本的研究
Neurol Ther. 2025 Jun 10. doi: 10.1007/s40120-025-00766-2.
2
Clinical, Humanistic, and Economic Value of 'Good ON-Time' in Advanced Parkinson's Disease: A Multinational Real-World Study.晚期帕金森病中“良好按时性”的临床、人文及经济价值:一项跨国真实世界研究
Neurol Ther. 2025 Jun 2. doi: 10.1007/s40120-025-00765-3.
3
The association between non-motor symptoms and cost in Parkinson's disease.
帕金森病中非运动症状与成本之间的关联。
J Neurol. 2025 Mar 28;272(4):297. doi: 10.1007/s00415-025-13044-w.
4
Therapies for Advanced Parkinson's Disease in Sweden: A Cost-Effectiveness Analysis Using Real-World Data.瑞典晚期帕金森病的治疗方法:一项使用真实世界数据的成本效益分析。
Neurol Ther. 2025 Jun;14(3):801-812. doi: 10.1007/s40120-025-00730-0. Epub 2025 Mar 21.
5
An analysis of curative care expenditure for Parkinson's disease under different comorbidity conditions: an empirical study based on China.不同合并症情况下帕金森病的治愈性护理支出分析:基于中国的实证研究
BMC Geriatr. 2025 Mar 7;25(1):159. doi: 10.1186/s12877-025-05790-3.
6
Balance and gait disorders in de novo Parkinson's disease: support for early rehabilitation.初发帕金森病的平衡和步态障碍:早期康复的依据
J Neurol. 2024 Dec 12;272(1):11. doi: 10.1007/s00415-024-12804-4.
7
Levodopa-entacapone-carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease.左旋多巴-恩他卡朋-卡比多巴肠凝胶:来自瑞典帕金森病国家登记处的数据。
Eur J Neurol. 2025 Jan;32(1):e16582. doi: 10.1111/ene.16582.
8
The rise of Parkinson's disease is a global challenge, but efforts to tackle this must begin at a national level: a protocol for national digital screening and "eat, move, sleep" lifestyle interventions to prevent or slow the rise of non-communicable diseases in Thailand.帕金森病的增加是一项全球性挑战,但应对这一挑战的努力必须从国家层面开始:泰国一项关于全国数字筛查以及“饮食、运动、睡眠”生活方式干预以预防或减缓非传染性疾病增加的方案。
Front Neurol. 2024 May 13;15:1386608. doi: 10.3389/fneur.2024.1386608. eCollection 2024.
9
Medication adherence and costs of medical care among patients with Parkinson's disease: an observational study using electronic medical records.帕金森病患者的药物依从性和医疗费用:一项基于电子病历的观察性研究。
BMC Public Health. 2024 Apr 30;24(1):1202. doi: 10.1186/s12889-024-18431-y.
10
Profiling chronic diseases and hospitalizations in older home care recipients: a nationwide cohort study in Sweden.分析老年居家护理接受者的慢性病和住院情况:瑞典全国队列研究。
BMC Geriatr. 2024 Apr 3;24(1):312. doi: 10.1186/s12877-024-04796-7.